Two trials that used PCWG-@ guidelines to define progression were analysed : a randomized phase II trial ( n = @ ) comparing first-line docetaxel-prednisone plus AT-@ or placebo , and a phase III trial ( n = @ ) comparing prednisone plus sunitinib or placebo after docetaxel-based chemotherapy .